Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 11/20 | 0.78 |
| ▸ | SRC | P12931 | 2/20 | 0.74 |
| ▸ | BTK | Q06187 | 3/20 | 0.72 |
| ▸ | EGFR | P00533 | 4/20 | 0.69 |
| ▸ | JAK3 | P52333 | 2/20 | 0.69 |
| ▸ | ITK | Q08881 | 1/20 | 0.68 |
| ▸ | TEC | P42680 | 1/20 | 0.68 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.68 |
| ▸ | JAK2 | O60674 | 1/20 | 0.67 |
| ▸ | JAK1 | P23458 | 1/20 | 0.67 |
| ▸ | BRD2 | P25440 | 1/20 | 0.67 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.67 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31684788 | 1.00 | BRD4 (0.78) | BRD4SRCBTKEGFRJAK3 | |
| SCHEMBL28980990 | 0.93 | SRC (0.69) | BRD4SRCBTKEGFRJAK3 | |
| SCHEMBL18371442 | 0.91 | EGFR (0.79) | BRD4SRCBTKEGFRITK | |
| SCHEMBL31684778 | 0.91 | BTK (0.80) | BRD4SRCBTKEGFRJAK3 | |
| SCHEMBL28980968 | 0.91 | BTK (0.80) | BRD4SRCBTKEGFRJAK3 | |
| SCHEMBL18371455 | 0.91 | EGFR (0.79) | BRD4SRCBTKEGFRJAK3 | |
| SCHEMBL28980983 | 0.90 | EGFR (0.72) | BRD4SRCBTKEGFRJAK3 | |
| SCHEMBL31684784 | 0.90 | EGFR (0.72) | BRD4SRCBTKEGFRJAK3 | |
| SCHEMBL18371443 | 0.89 | SRC (0.67) | BRD4SRCBTKEGFRJAK3 | |
| SCHEMBL265060 | 0.88 | BRD4 (0.82) | BRD4JAK3JAK2JAK1BRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115894381-A | 2,4,5-trisubstituted pyrimidine compound and preparation method and application thereof | 温州医科大学 | 2023-04-04 | — | — | CN | claimed |
| CN-115894381-A | 2,4,5-trisubstituted pyrimidine compound and preparation method and application thereof | 温州医科大学 | 2023-04-04 | — | — | CN | disclosed |
| US-20170008856-A1 | SUBSTITUTED PYRIMIDINES USEFUL AS EGFR-T790M KINASE INHIBITORS | JIANGSU MEDOLUTION LTD (CN) | 2017-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170008856-A1 | SUBSTITUTED PYRIMIDINES USEFUL AS EGFR-T790M KINASE INHIBITORS | EGFR, ERBB2, ERBB3 | BRD4 1328/4885SRC 124/4885BTK 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.